Journal
BLOOD ADVANCES
Volume 6, Issue 2, Pages 376-385Publisher
ELSEVIER
DOI: 10.1182/bloodadvances.2021005642
Keywords
-
Categories
Funding
- National Institutes of Health, National Cancer Institute Cancer Clinical Investigator Team Leadership Award (CCITLA)
- Dennis Cooper Hematology Young Investigator Award
- National Cancer Institute of the National Institutes of Health [P30 CA016359]
Ask authors/readers for more resources
This study aimed to describe the characteristics, clinical treatment patterns, and adverse outcomes of patients with acute promyelocytic leukemia (APL). The results showed that a substantial proportion of patients did not receive guideline-concordant therapy, potentially contributing to adverse outcomes.
Acute promyelocytic leukemia (APL) is associated with a favorable long-term prognosis if appropriate treatment is initiated promptly. Outcomes in clinical trials and populationbased registries vary; potential explanations include a delay in treatment and lower adherence to guideline-recommended therapy in real-world practice. We used the Vizient Clinical Data Base to describe demographic characteristics, baseline clinical characteristics, and treatment patterns in patients newly diagnosed with APL during the study period of April 2017 to March 2020. Baseline white blood cell count was used to assign risk status and assess treatment concordance with National Comprehensive Cancer Network guidelines. Logistic regression models examined adjusted associations between patient, hospital, disease characteristics, and adverse outcomes (in-hospital death or discharge to hospice). Among 1464 patients with APL, 205 (14.0%) experienced an adverse outcome. A substantial subset (20.6%) of patients did not receive guideline-concordant regimens. Odds of adverse outcomes increased with failure to receive guideline-concordant treatment (odds ratio [OR], 2.31; 95% confidence interval [CI], 1.43-3.75; P = .001), high-risk disease (OR, 2.48; 95% CI, 1.53-4.00; P .001), and increasing age ( _50 vs 200 AML patients per year]; P = .046). In conclusion, in this large database analysis, 14.0% of patients newly diagnosed with APL died or were discharged to hospice. A substantial proportion of patients did not receive guideline-concordant therapy, potentially contributing to adverse outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available